Biomarker ID | 242 |
PMID | 18196514 |
Year | 2008 |
Biomarker | CXCL12 |
Biomarker Basis | Expression Based |
Biomolecule | Protein |
Source | Serum |
Subjects | Humans |
Regulation | Upregulated in Biopsy Positive Patients |
Odds Ratio/Hazard Ratio/Relative Risk | NA |
Effect on Pathways | Pathways Include:-Binding of chemokines to chemokine receptors, Nuclear signaling by ErbB4,Intestinal immune network for IgA production,HIF-1 transcriptional activity in hypoxia,Interleukin-7 interactions in immune response |
Experiment | Biopsy Negative Patients And Biopsy Positive Patients for Prostate Cancer |
Type of Biomarker | Diagnostic |
Cohort | 51 men were included in this study. 25 men presented with BPH (17 with negative biopsies and 8 with positive biopsies). 14 were detected with Prostate Cancer. |
Senstivity | NA |
Specificity | NA |
AUC | NA |
Accuracy | NA |
Level Of Significance | p=0.05 |
Method Used | Sandwich ELISA |
Clinical | No |
Remarks | NA |
Clinical Trial Number | NA |
Degree Of Validity | Not validated on independent patient dataset |
Technical Name | CXCL12 |